Oncology Fusion Gene Only NGS Panel
| Abbrev Code: | RNAFUS | ||
| Order Code: | LAB8096 | Order Name: | Oncology Fusion Gene Only NGS Panel |
| Synonyms: | NGS Fusion Profile; ALK; ROS1; NTRK1; NTRK3; RET; MET | ||
| Methodology: | Next generation sequencing | ||
| CPT Codes: | G0452 x1, G0452 x1, 81456 x1, 81456 x1 | ||
| Test Includes: | AKT1, AKT3, ALK, AR, ARHGAP26, AXL, BCOR, BRAF, BRD3, BRD4, CAMTA1, CCNB3, CCND1, CD274, CIC, CSF1, CSF1R, CTNNB1, DNAJB1, ERBB4, EGFR, EPC1, ERBB2, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, GRB7, FOXR2, FUS, GLI1, HMGA2, HRAS, IDH1, IDH2, INSR, JAK2, JAK3, JAZF1, KRAS, MAML2, MAP2K1, MAST1, MAST2, MEAF6, MET, MUSK, MYB, MLK2, MN1, MSMB, MYBL1, MYOD1, NCOA1, NCOA2, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PHF1, PIK3CA, PDGFB, PDGFRA, PDGFRB, PKN1, PLAG1, PPARG, PRKACA, PRKCA, PRKCB, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SS18, STAT6, TFE3, TFEB, TFG, TAF15, TCF12, TERT, THADA, TMPRSS2, USP6, VGLL2, YAP1, YWHAE | ||
| Turnaround Time: | Performed Mon-Fri; results are reported within 10-14 days. | ||
| Special Instructions: | Fixed samples: Include block number for testing. | ||
Collection Instructions
| Specimen: | Fresh tissue slides; fresh tissue |
| Optimal Volume: | 5 unstained slides (10 microns thick) and 1 H&E slide (10 microns thick) fixed tissue |
| Minimum\Peds Volume: | 5 unstained slides (10 microns thick) and 1 H&E slide (10 microns thick) fixed tissue |
| Container: | Plastic leakproof container, sterile |
| Causes for Rejection: | Tissue: decalcified tissue, fixatives other than formalin used. Samples containing less than 10% tumor will not be tested. |
Processing and Shipping
| Specimen Processing: | Do not process. Store at room temperature. |
| Shipping Instructions: | Ship at room temperature. Do not refrigerate or freeze. |
| Stability: | Do not refrigerate or freeze. |
| Test Performed at or Referral Lab | UM Molecular Diagnostics (M) (UMMC East Bank) |
Interpretive
| Reference Range: | See interpretive report. |
| Use: | The NGS Oncology (NGSO) Pan Tumor Fusion assay is an RNA-based Next Generation Sequencing assay validated for the detection of a wide spectrum of oncogenic fusions in solid tumors and sarcomas which predict therapeutic response or provide diagnostic information on tumor type. The assay comprehensively targets 109 genes and utilizes anchored multiplex PCR (AMP) chemistry to enable detection of known and unknown fusion partners with the listed genes.
This assay is intended to detect fusions involving NTRK 1/2/3, ALK, ROS, RET, FGFR1/2/3, which have approved targeted therapies as well as other fusions which may provide eligibility for clincal trials. The assay is also intended to detect diagnostic fusions in numerous clinical contexts including: soft tissue sarcomas, CNS malignancies, and head and neck malignancies. |
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
[email protected] for TestID: 6728"